CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 800 enrolled
Drug / intervention
Abciximab +1 moredrug
Likely dose
Abciximab 5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00133250
NCT00133250Phase 4Completed
CompareCT.gov

Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)

Deutsches Herzzentrum Muenchen·interventional·Posted Aug 23, 2005·Updated Mar 16, 2010

In Brief

A Phase 4 clinical trial evaluating Abciximab and Placebo Heparin Sodium for Myocardial Infarction. Completed, enrolled 800 participants across 5 sites in 2 countries.

Detailed Summary

The purpose of this study is to assess whether abciximab is associated with additional benefit in patients with AMI treated with PCI after high dose clopidogrel loading.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Infarction
CountriesAustria, Germany
CollaboratorsTechnical University of Munich

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 23, 2005
Enrollment StartJun 1, 2003
Primary CompletionFeb 1, 2008
Study CompletionMar 1, 2008
TodayJul 1, 2026
Enrollment to primary: 4.7 yearsPosted 20.9 years ago

Interventions

Abciximabdrug

Abciximab bolus and infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 10 mg abciximab. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.

Placebo Heparin Sodiumother

Placebo bolus plus infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 3000 U Heparin. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.